Hair growth / androgenetic alopecia
HairMax LaserComb randomized sham-controlled trial in male androgenetic alopecia
Leavitt M, Charles G, Heyman E, Michaels D. Clinical Drug Investigation. 2009.
This multicenter double-blind sham-device-controlled trial tested a handheld 655 nm HairMax LaserComb in men with androgenetic alopecia.
Evidence grade
moderate
Effect direction
positive
Panel relevance
not-panel-replicable
Key findings
- The 110 completers using the active LaserComb had significantly greater mean terminal hair density than sham at 26 weeks.
- Patient subjective assessment of overall hair regrowth also favored active treatment.
- The device was well tolerated with no serious adverse events and no statistical difference in adverse effects between groups.
Protocol details
| Wavelengths | 655 nm |
|---|---|
| Irradiance | Not reported mW/cm2 |
| Fluence | Not reported J/cm2 |
| Session time | Not reported minutes |
| Frequency | Not reported |
| Duration | 26 weeks |
| Treatment area | Scalp |
| Device type | Handheld laser comb that parts hair to deliver light to scalp |
Caveats
- This supports scalp-contact or near-scalp comb devices, not distant body panels.
- The study enrolled males with specific androgenetic alopecia classifications.